AIM ImmunoTech Inc. (AIM)
USD 0.09
(-19.37%)
USD 0.09
(-19.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 495 Thousand USD | -24.89% |
| 2022 | 659 Thousand USD | 488.39% |
| 2021 | 112 Thousand USD | -94.42% |
| 2020 | 2 Million USD | -67.23% |
| 2019 | 6.12 Million USD | 164.37% |
| 2018 | 2.31 Million USD | 26.32% |
| 2017 | 1.83 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 23 Thousand USD | -58.18% |
| 2012 | 55 Thousand USD | -88.52% |
| 2011 | 479 Thousand USD | 398.96% |
| 2010 | 96 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 3.21 Million USD | 954.75% |
| 2004 | 305 Thousand USD | -85.18% |
| 2003 | 2.05 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 950 Thousand USD | 0.0% |
| 2024 Q2 | 283 Thousand USD | -70.21% |
| 2023 Q3 | 543 Thousand USD | -9.05% |
| 2023 FY | 495 Thousand USD | -24.89% |
| 2023 Q4 | 495 Thousand USD | -8.84% |
| 2023 Q2 | 597 Thousand USD | -6.13% |
| 2023 Q1 | 636 Thousand USD | -3.49% |
| 2022 Q1 | 84 Thousand USD | -25.0% |
| 2022 FY | 659 Thousand USD | 488.39% |
| 2022 Q4 | 659 Thousand USD | -5.18% |
| 2022 Q3 | 695 Thousand USD | -5.44% |
| 2022 Q2 | 735 Thousand USD | 775.0% |
| 2021 Q3 | 108 Thousand USD | 2.86% |
| 2021 FY | 112 Thousand USD | -94.42% |
| 2021 Q4 | 112 Thousand USD | 3.7% |
| 2021 Q1 | 1.93 Million USD | -3.64% |
| 2021 Q2 | 105 Thousand USD | -94.57% |
| 2020 Q3 | 2.08 Million USD | -0.53% |
| 2020 Q4 | 2 Million USD | -3.46% |
| 2020 FY | 2 Million USD | -67.23% |
| 2020 Q1 | 6.35 Million USD | 3.69% |
| 2020 Q2 | 2.09 Million USD | -67.09% |
| 2019 Q4 | 6.12 Million USD | 40.13% |
| 2019 FY | 6.12 Million USD | 164.37% |
| 2019 Q2 | 4.63 Million USD | -23.36% |
| 2019 Q3 | 4.37 Million USD | -5.73% |
| 2019 Q1 | 6.05 Million USD | 161.13% |
| 2018 Q3 | 2.36 Million USD | -1.99% |
| 2018 FY | 2.31 Million USD | 26.32% |
| 2018 Q4 | 2.31 Million USD | -2.15% |
| 2018 Q2 | 2.41 Million USD | -0.9% |
| 2018 Q1 | 2.43 Million USD | 32.92% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | 1.83 Million USD | 0.0% |
| 2017 Q4 | 1.83 Million USD | 25.17% |
| 2017 Q3 | 1.46 Million USD | 183.56% |
| 2017 Q2 | 517 Thousand USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | 29 Thousand USD | 26.09% |
| 2014 Q3 | 3000.00 USD | -85.0% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q2 | 20 Thousand USD | -31.03% |
| 2013 Q3 | 97 Thousand USD | -31.21% |
| 2013 Q4 | 23 Thousand USD | -76.29% |
| 2013 Q1 | 251 Thousand USD | 356.36% |
| 2013 Q2 | 141 Thousand USD | -43.82% |
| 2013 FY | 23 Thousand USD | -58.18% |
| 2012 Q2 | 73 Thousand USD | -15.12% |
| 2012 Q3 | 64 Thousand USD | -12.33% |
| 2012 FY | 55 Thousand USD | -88.52% |
| 2012 Q4 | 55 Thousand USD | -14.06% |
| 2012 Q1 | 86 Thousand USD | -82.05% |
| 2011 Q1 | 96 Thousand USD | 0.0% |
| 2011 FY | 479 Thousand USD | 398.96% |
| 2011 Q3 | 112 Thousand USD | -8.94% |
| 2011 Q2 | 123 Thousand USD | 28.13% |
| 2011 Q4 | 479 Thousand USD | 327.68% |
| 2010 Q1 | 30 Thousand USD | 0.0% |
| 2010 Q2 | 21 Thousand USD | -30.0% |
| 2010 Q4 | 96 Thousand USD | -14.29% |
| 2010 FY | 96 Thousand USD | 0.0% |
| 2010 Q3 | 112 Thousand USD | 433.33% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | 3.52 Million USD | 9.54% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 FY | 3.21 Million USD | 954.75% |
| 2005 Q1 | 181 Thousand USD | -40.66% |
| 2005 Q4 | 3.21 Million USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q1 | 1.91 Million USD | -6.9% |
| 2004 Q4 | 305 Thousand USD | -68.16% |
| 2004 Q3 | 958 Thousand USD | -53.38% |
| 2004 Q2 | 2.05 Million USD | 7.25% |
| 2004 FY | 305 Thousand USD | -85.18% |
| 2003 Q4 | 2.05 Million USD | 112.38% |
| 2003 Q3 | 969 Thousand USD | 0.0% |
| 2003 FY | 2.05 Million USD | 0.0% |
| 2003 Q1 | 638 Thousand USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 99.399% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | 68.511% |
| Azitra, Inc. | 563.69 Thousand USD | 12.186% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -3707.692% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | 75.971% |
| CEL-SCI Corporation | 11.6 Million USD | 95.734% |
| iBio, Inc. | 3.5 Million USD | 85.885% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 76.087% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 82.902% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 73.554% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | 55.325% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 90.837% |
| BiomX Inc. | 5.4 Million USD | 90.837% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | 89.288% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -202.231% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 96.076% |
| Theriva Biologics, Inc. | 162 Thousand USD | -205.556% |